Webinar

Predicting Response and Personalizing Treatment Decisions in Mental Health: New Opportunities with AI and Real-World Data

Available on-demand

60 Minutes

Mental health conditions can take a significant toll on an individual—physically, socially, and financially. Despite new treatment options becoming available, many patients still continue to struggle with finding effective solutions. Frustratingly, even treatments with strong efficacy won’t work for everyone - and it’s very hard to know in advance who will or won’t respond.

It is more important than ever to be able to precisely identify patients with and at risk for treatment resistance to break this cycle, broadening access to advanced therapies, and improving outcomes. Join us for this timely and insightful webinar to explore the latest strategies that leverage AI technology and Real-World Data (RWD) to enhance research and transform the mental health care landscape.

We’ll discuss:

A deep dive into Treatment-Resistant Depression, going beyond the traditional criterion of two antidepressant trials of adequate dose and duration
The 'gold standard' for capturing treatment resistance based on psychiatrists’ clinical assessments captured in electronic health records
How to use AI to identify and locate patients with treatment resistance in real-world data sources
Connecting patterns in data to patients at risk, and the physicians who can help them
Additional AI use cases for addressing other challenges in mental health care
And more

Don’t miss this informative session on how AI and real-world data are contributing to a deeper understanding of mental health conditions and advancing the development of more effective, personalized interventions.

Speakers

Joseph Zabinski, PhD, MEM

VP, Head of Commercial Strategy & AI

OM1

Joseph Zabinski, PhD, MEM is VP, Head of Commercial Strategy & AI at OM1. He oversees design, implementation, and evolution of OM1's commercial strategy, including prioritization, go-to-market planning, and alignment with emergent market needs. Dr. Zabinski also serves as subject matter expert and thought leader for OM1's AI work, including applications of the PhenOM digital phenotyping platform with life science and healthcare provider partners.

Carl Marci, MD

Chief Clinical Officer and Chief Psychiatrist and Managing Director of Mental Health and Neuroscience

OM1

Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School. He completed two NIH Fellowships in neuroscience, published numerous articles in peer-review journals, and is the author of Rewired: Protecting Your Brain in the Digital Age. Dr. Marci is a graduate of Columbia University, Oxford University as a Rhodes Scholar and Harvard Medical School. He is also a member of the Aspen Global Leadership Network and winner of the 2023 PharmaVoice 100 award for health care innovation.

Register here to watch on-demand!

Already registered? Click here to login.